Mark Lappe, Chief Executive Officer at Inhibrx Biosciences, Inc. (INBX), bought 80,000 shares at $12.97 ($1.0M) on 2024-08-20, disclosed to the SEC on 2024-08-22.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.97 | 27,055 | $351K | 33.9% |
| 2 | $12.97 | 27,055 | $351K | 33.9% |
| 3 | $12.93 | 12,945 | $167K | 16.1% |
| 4 | $12.93 | 12,945 | $167K | 16.1% |
| Total | $12.96 avg | 80,000 | $1.0M | 100% |
| Filing → |
| INBX | BUY | 2024-09-10 | $671K | — | Filing → |
| INBX | BUY | 2024-09-03 | $913K | — | Filing → |
| INBX | SELL | 2023-03-01 | $2K | — | Filing → |